{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T10:52:21Z","timestamp":1771757541507,"version":"3.50.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,27]],"date-time":"2020-01-27T00:00:00Z","timestamp":1580083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,1,27]],"date-time":"2020-01-27T00:00:00Z","timestamp":1580083200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Swedish Breast Cancer Association"},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2015-00760"],"award-info":[{"award-number":["2015-00760"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","award":["2015\/437"],"award-info":[{"award-number":["2015\/437"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Nordic Cancer Union","award":["R217-A13260-18-S65"],"award-info":[{"award-number":["R217-A13260-18-S65"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2020,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Purpose<\/jats:title>\n<jats:p>None of the key randomised trials on the omission of axillary lymph node dissection (ALND) in sentinel lymph-positive breast cancer have reported external validity, even though results indicate selection bias. Our aim was to assess the external validity of the ongoing randomised SENOMAC trial by comparing characteristics of Swedish SENOMAC trial participants with non-included eligible patients registered in the Swedish National Breast Cancer Register (NKBC).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>In the ongoing non-inferiority European SENOMAC trial, clinically node-negative cT1\u2013T3 breast cancer patients with up to two sentinel lymph node macrometastases are randomised to undergo completion ALND or not. Both breast-conserving surgery and mastectomy are eligible interventions. Data from NKBC were extracted for the years 2016 and 2017, and patient and tumour characteristics compared with Swedish trial participants from the same years.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Overall, 306 NKBC cases from non-participating and 847 NKBC cases from participating sites (excluding SENOMAC participants) were compared with 463 SENOMAC trial participants. Patients belonging to the middle age groups (<jats:italic>p<\/jats:italic>\u2009=\u20090.015), with smaller tumours (<jats:italic>p<\/jats:italic>\u2009=\u20090.013) treated by breast-conserving therapy (50.3 versus 47.1 versus 65.2%, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) and less nodal tumour burden (only 1 macrometastasis in 78.8 versus 79.9 versus 87.3%, <jats:italic>p<\/jats:italic>\u2009=\u20090.001) were over-represented in the trial population. Time trends indicated, however, that differences may be mitigated over time.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>This interim external validity analysis specifically addresses selection mechanisms during an ongoing trial, potentially increasing generalisability by the time full accrual is reached. Similar validity checks should be an integral part of prospective clinical trials.<\/jats:p>\n<jats:p>Trial registration: NCT 02240472, retrospective registration date September 14, 2015 after trial initiation on January 31, 2015<\/jats:p>\n<\/jats:sec>","DOI":"10.1007\/s10549-020-05537-1","type":"journal-article","created":{"date-parts":[[2020,1,27]],"date-time":"2020-01-27T14:02:43Z","timestamp":1580133763000},"page":"167-176","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["The generalisability of randomised clinical trials: an interim external validity analysis of the ongoing SENOMAC trial in sentinel lymph node-positive breast cancer"],"prefix":"10.1007","volume":"180","clinical-trial-number":[{"clinical-trial-number":"nct02240472","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9518-0902","authenticated-orcid":false,"given":"Jana","family":"de Boniface","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johan","family":"Ahlgren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yvette","family":"Andersson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leif","family":"Bergkvist","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Frisell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Lundstedt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger","family":"Olofsson Bagge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Ryd\u00e9n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malin","family":"Sund","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"the SENOMAC Trialists\u2019 Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peer","family":"Christiansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tove","family":"Filtenborg Tvedskov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Birgitte Vrou","family":"Offersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toralf","family":"Reimer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thorsten","family":"K\u00fchn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michalis","family":"Kontos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oreste","family":"Gentilini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roland","family":"Reitsamer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,1,27]]},"reference":[{"issue":"4","key":"5537_CR1","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/S1470-2045(13)70035-4","volume":"14","author":"V Galimberti","year":"2013","unstructured":"Galimberti V, Cole BF, Zurrida S, Viale G, Luini A, Veronesi P, Baratella P, Chifu C, Sargenti M, Intra M, Gentilini O, Mastropasqua MG, Mazzarol G, Massarut S, Garbay JR, Zgajnar J, Galatius H, Recalcati A, Littlejohn D, Bamert M, Colleoni M, Price KN, Regan MM, Goldhirsch A, Coates AS, Gelber RD, Veronesi U (2013) Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. Lancet Oncol 14(4):297\u2013305","journal-title":"Lancet Oncol"},{"issue":"6","key":"5537_CR2","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1001\/jama.2011.90","volume":"305","author":"AE Giuliano","year":"2011","unstructured":"Giuliano AE, Hunt KK, Ballman KV, Beitsch PD, Whitworth PW, Blumencranz PW, Leitch AM, Saha S, McCall LM, Morrow M (2011) Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA 305(6):569\u2013575","journal-title":"JAMA"},{"issue":"12","key":"5537_CR3","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1016\/S1470-2045(14)70460-7","volume":"15","author":"M Donker","year":"2014","unstructured":"Donker M, van Tienhoven G, Straver ME, Meijnen P, van de Velde CJ, Mansel RE, Cataliotti L, Westenberg AH, Klinkenbijl JH, Orzalesi L, Bouma WH, van der Mijle HC, Nieuwenhuijzen GA, Veltkamp SC, Slaets L, Duez NJ, de Graaf PW, van Dalen T, Marinelli A, Rijna H, Snoj M, Bundred NJ, Merkus JW, Belkacemi Y, Petignat P, Schinagl DA, Coens C, Messina CG, Bogaerts J, Rutgers EJ (2014) Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol 15(12):1303\u20131310","journal-title":"Lancet Oncol"},{"issue":"4","key":"5537_CR4","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.ejso.2016.12.011","volume":"43","author":"A Savolt","year":"2017","unstructured":"Savolt A, Peley G, Polgar C, Udvarhelyi N, Rubovszky G, Kovacs E, Gyorffy B, Kasler M, Matrai Z (2017) Eight-year follow up result of the OTOASOR trial: the optimal treatment of the axilla-surgery or radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: a randomized, single centre, phase III, non-inferiority trial. Eur J Surg Oncol 43(4):672\u2013679","journal-title":"Eur J Surg Oncol"},{"issue":"2","key":"5537_CR5","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1055\/s-0042-122853","volume":"77","author":"T Reimer","year":"2017","unstructured":"Reimer T, Stachs A, Nekljudova V, Loibl S, Hartmann S, Wolter K, Hildebrandt G, Gerber B (2017) Restricted axillary staging in clinically and sonographically node-negative early invasive breast cancer (c\/iT1-2) in the context of breast conserving therapy: first results following commencement of the intergroup-sentinel-mamma (INSEMA) Trial. Geburtshilfe Frauenheilkd 77(2):149\u2013157","journal-title":"Geburtshilfe Frauenheilkd"},{"issue":"1","key":"5537_CR6","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1186\/s12885-017-3361-y","volume":"17","author":"J de Boniface","year":"2017","unstructured":"de Boniface J, Frisell J, Andersson Y, Bergkvist L, Ahlgren J, Ryden L, Olofsson Bagge R, Sund M, Johansson H, Lundstedt D (2017) Survival and axillary recurrence following sentinel node-positive breast cancer without completion axillary lymph node dissection: the randomized controlled SENOMAC trial. BMC Cancer 17(1):379","journal-title":"BMC Cancer"},{"issue":"12","key":"5537_CR7","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.clon.2015.07.005","volume":"27","author":"A Goyal","year":"2015","unstructured":"Goyal A, Dodwell D (2015) POSNOC: A randomised trial looking at axillary treatment in women with one or two sentinel nodes with macrometastases. Clin Oncol 27(12):692\u2013695","journal-title":"Clin Oncol"},{"issue":"5","key":"5537_CR8","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/j.breast.2012.06.013","volume":"21","author":"O Gentilini","year":"2012","unstructured":"Gentilini O, Veronesi U (2012) Abandoning sentinel lymph node biopsy in early breast cancer? A new trial in progress at the European Institute of Oncology of Milan (SOUND: Sentinel node vs Observation after axillary UltraSouND). Breast 21(5):678\u2013681","journal-title":"Breast"},{"issue":"5","key":"5537_CR9","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1056\/NEJMra1510059","volume":"375","author":"I Ford","year":"2016","unstructured":"Ford I, Norrie J (2016) Pragmatic trials. N Engl J Med 375(5):454\u2013463","journal-title":"N Engl J Med"},{"issue":"10","key":"5537_CR10","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1001\/jama.2017.11470","volume":"318","author":"AE Giuliano","year":"2017","unstructured":"Giuliano AE, Ballman KV, McCall L, Beitsch PD, Brennan MB, Kelemen PR, Ollila DW, Hansen NM, Whitworth PW, Blumencranz PW, Leitch AM, Saha S, Hunt KK, Morrow M (2017) Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial. JAMA 318(10):918\u2013926","journal-title":"JAMA"},{"issue":"2","key":"5537_CR11","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s10549-018-4820-0","volume":"171","author":"Y Andersson","year":"2018","unstructured":"Andersson Y, Bergkvist L, Frisell J, de Boniface J (2018) Long-term breast cancer survival in relation to the metastatic tumor burden in axillary lymph nodes. Breast Cancer Res Treat 171(2):359\u2013369","journal-title":"Breast Cancer Res Treat"},{"key":"5537_CR12","unstructured":"Register NKBC. Online statistics. https:\/\/statistik.incanet.se\/brostcancer\/."},{"key":"5537_CR13","unstructured":"Register NKBC (2015) Validering av Nationellt kvalitetsregister f\u00f6r br\u00f6stcancer. https:\/\/www.cancercentrum.se\/globalassets\/cancerdiagnoser\/brost\/kvalitetsregister\/rapport_master_validering_brostregister2015-10-14.pdf."},{"issue":"8","key":"5537_CR14","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/0021-9681(67)90041-0","volume":"20","author":"D Schwartz","year":"1967","unstructured":"Schwartz D, Lellouch J (1967) Explanatory and pragmatic attitudes in therapeutical trials. J Chronic Dis 20(8):637\u2013648","journal-title":"J Chronic Dis"},{"issue":"9","key":"5537_CR15","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1097\/BSD.0000000000000588","volume":"30","author":"Z Merali","year":"2017","unstructured":"Merali Z, Wilson JR (2017) Explanatory versus pragmatic trials: an essential concept in study design and interpretation. Clin Spine Surg 30(9):404\u2013406","journal-title":"Clin Spine Surg"},{"issue":"9453","key":"5537_CR16","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/S0140-6736(04)17670-8","volume":"365","author":"PM Rothwell","year":"2005","unstructured":"Rothwell PM (2005) External validity of randomised controlled trials: \"to whom do the results of this trial apply?\". Lancet 365(9453):82\u201393","journal-title":"Lancet"},{"key":"5537_CR17","doi-asserted-by":"publisher","first-page":"h2147","DOI":"10.1136\/bmj.h2147","volume":"350","author":"K Loudon","year":"2015","unstructured":"Loudon K, Treweek S, Sullivan F, Donnan P, Thorpe KE, Zwarenstein M (2015) The PRECIS-2 tool: designing trials that are fit for purpose. BMJ 350:h2147","journal-title":"BMJ"},{"key":"5537_CR18","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.archger.2017.05.017","volume":"72","author":"M Thake","year":"2017","unstructured":"Thake M, Lowry A (2017) A systematic review of trends in the selective exclusion of older participant from randomised clinical trials. Arch Gerontol Geriatr 72:99\u2013102","journal-title":"Arch Gerontol Geriatr"},{"key":"5537_CR19","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.canep.2017.11.002","volume":"51","author":"C Dunn","year":"2017","unstructured":"Dunn C, Wilson A, Sitas F (2017) Older cancer patients in cancer clinical trials are underrepresented. Systematic literature review of almost 5000 meta- and pooled analyses of phase III randomized trials of survival from breast, prostate and lung cancer. Cancer Epidemiol 51:113\u2013117","journal-title":"Cancer Epidemiol"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-020-05537-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-020-05537-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-020-05537-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T15:52:34Z","timestamp":1628610754000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-020-05537-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,27]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["5537"],"URL":"https:\/\/doi.org\/10.1007\/s10549-020-05537-1","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,27]]},"assertion":[{"value":"14 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All listed authors declare that they have no conflict of interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The SENOMAC trial received ethical permission from the Ethics Committee at Karolinska Institutet, Stockholm, Sweden, in 2014 (2014\/1165-31\/1), with an amendment in 2017 to allow for comparative analysis with NKBC data (2017\/1986-32).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}